Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.

Description

11 parts

›This application claims priority from Korean Patent Application…

This application claims priority from Korean Patent Application No. 2003-90559, filed on Dec. 12, 2003, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein in its entirety by reference.

›BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to PCR primer sets for detecting severe acute respiratory syndrome (SARS) virus, a method and a kit for detecting SARS virus.

2. Description of the Related Art

Severe acute respiratory syndrome (SARS) virus is a new type of coronavirus and is designated as SARS-Coronavirus (hereinafter, referred to as “SARS-CoV”) by the World Health Organization (WHO). It is known that SARS-CoV gives rise to severe acute respiratory syndrome. SARS-CoV is a novel RNA virus. It is known that the whole genome sequence of SARS-CoV consists of about 29,730 bp and the genetic makeup is similar to those of other types of coronaviruses.

The WHO reported guidelines for laboratory diagnosis of SARS as follows: (a) antibody test: identification of SARS-CoV antibody in serum after one day, (b) PCR (Polymerase Chain Reaction) test: identification of SARS-CoV RNA by PCR, and (c) virus separation: separation of SARS-CoV.

In a conventional PCR test, the following six types of primers are used for detection of SARS-CoV:

(1) BNIoutS2: SEQ ID NO: 29 (24mer); BNIoutAs: SEQ ID NO: 30 (21mer), BNIinS: SEQ ID NO: 31 (20mer); BNIinAs: SEQ ID NO: 32 (22mer), (2) SAR1S: SEQ ID NO: 33 (21mer); SAR1As: SEQ ID NO: 34 (21mer), (3) Cor-p-F2: SEQ ID NO: 35 (21 mer); Cor-p-R1: SEQ ID NO: 34 (21 mer), (4) Cor-p-F3: SEQ ID NO: 35 (21mer); Cor-p-R1: SEQ ID NO: 36 (21mer), (5) COR-1: SEQ ID NO: 37 (26mer); COR-2: SEQ ID NO: 38 (26mer), (6) HKU (sense): SEQ ID NO: 39 (17mer); HKU (antisense): SEQ ID NO: 40 (16mer).

Among them, the primers of (1), which were developed by Bernhard-Nocht Institute (BNI, Germany) for diagnosis of SARS generated in early 2003, have been most widely used. However, only a local region, i.e., a polymerase gene region, of the whole genome sequence of about 30 kb of SARS-CoV, is used as a target site of currently known primers. Such a narrow application site may lead to either false negative or false positive results.

In view of these problems, the present inventors found SARS-CoV-specific primers which reduce a likelihood of being determined as false negative or false positive and rapidly detect SARS-CoV in situ after rapid PCR, and completed the present invention.

›SUMMARY OF THE INVENTION

The present invention provides SARS-CoV-specific primer sets.

The present invention also provides a method for specifically detecting SARS-CoV using the primer sets.

The present invention also provides a SARS-CoV detection kit including the primer set.

According to an aspect of the present invention, there is provided a PCR primer set for SARS-CoV detection selected from the group consisting of the following primer sets: (a) a primer set (GS-SARS01) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 1 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 2; (b) a primer set (GS-SARS02) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 3 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 4; (c) a primer set (GS-SARS03) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 5 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 6; (d) a primer set (GS-SARS04) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 7 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 8; (e) a primer set (GS-SARS05) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 9 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 10; (f) a primer set (GS-SARS06) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 11 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 12; (g) a primer set (GS-SARS07) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 13 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 14; (h) a primer set (GS-SARS08) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 15 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 16; (i) a primer set (GS-SARS09) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 17 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 18; (j) a primer set (GS-SARS10) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 19 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 20; (k) a primer set (GS-SARS11) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 21 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 22; (l) a primer set (GS-SARS12) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 23 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 24; (m) a primer set (GS-SARS13) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 25 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 26; (n) a primer set (GS-SARS14) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 27 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 28; (o) a primer set (GS-SARS15) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 29 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 30; (p) a primer set (GS-SARS16) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 31 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 32; (q) a primer set (GS-SARS17) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 33 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 34; (r) a primer set (GS-SARS18) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 35 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 36; (s) a primer set (GS-SARS19) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 37 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 38; (t) a primer set (GS-SARS20) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 39 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 40; (u) a primer set (GS-SARS21) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 41 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 42; (v) a primer set (GS-SARS22) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 43 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 44; and (w) a primer set (GS-SARS23) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 45 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 46.

According to another aspect of the present invention, there is provided a method for detecting SARS-CoV, which includes amplifying a nucleic acid sample obtained from an individual by PCR using the primer set.

According to yet another aspect of the present invention, there is provided a SARS-CoV detection kit including the primer set.

›BRIEF DESCRIPTION OF THE DRAWINGS

The above and other features and advantages of the present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings in which:

FIG. 1 schematically illustrates target nucleotide sequences for PCR primers according to the present invention;

FIG. 2 illustrates tube RT-PCR results for SARS-CoV RNA samples using primers according to the present invention;

FIG. 3 illustrates PCR results for SARS-CoV RNA samples on a silicon-based PCR chip using primers according to the present invention; and

FIG. 4 illustrates PCR results for SARS-CoV RNA samples and human gDNA samples on a silicon-based PCR chip using primers according to the present invention.

›DETAILED DESCRIPTION OF THE INVENTION · 1 of 2

The present invention provides a PCR primer set selected from the group consisting of the following primer sets:

(a) a primer set (GS-SARS01) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 1 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 2;

(b) a primer set (GS-SARS02) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 3 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 4;

(c) a primer set (GS-SARS03) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 5 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 6;

(d) a primer set (GS-SARS04) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 7 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 8;

(e) a primer set (GS-SARS05) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 9 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 10;

(f) a primer set (GS-SARS06) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 11 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 12;

(g) a primer set (GS-SARS07) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 13 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 14;

(h) a primer set (GS-SARS08) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 15 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 16;

(i) a primer set (GS-SARS09) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 17 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 18;

(j) a primer set (GS-SARS10) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 19 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 20;

(k) a primer set (GS-SARS11) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 21 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 22;

(l) a primer set (GS-SARS12) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 23 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 24;

(m) a primer set (GS-SARS13) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 25 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 26;

(n) a primer set (GS-SARS14) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 27 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 28;

(o) a primer set (GS-SARS15) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 29 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 30;

(p) a primer set (GS-SARS16) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 31 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 32;

(q) a primer set (GS-SARS17) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 33 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 34;

(r) a primer set (GS-SARS18) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 35 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 36;

(s) a primer set (GS-SARS19) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 37 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 38;

(t) a primer set (GS-SARS20) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 39 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 40;

(u) a primer set (GS-SARS21) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 41 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 42;

(v) a primer set (GS-SARS22) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 43 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 44; and

(w) a primer set (GS-SARS23) including a primer having a nucleotide sequence as set forth in SEQ ID NO: 45 and a primer having a nucleotide sequence as set forth in SEQ ID NO: 46.

The primer sets of the present invention can specifically detect SARS-CoV without reacting with other coronaviruses. That is, when PCR is performed using the primer set of the present invention, PCR products are obtained from individuals infected with SARS-CoV but no PCR products are obtained from individuals infected with other coronaviruses. The PCR primer set for SARS-CoV detection of the present invention is selected from a non-structural region and a structural region among the genome sequence of SARS-CoV. SARS-CoV regions including target nucleotide sequences for the primers according to the present invention are illustrated in FIG. 1 .

The present invention also provides a method for detecting SARS-CoV, which comprises amplifying a nucleic acid sample obtained from an individual by PCR using the primer set for SARS-CoV detection.

As used herein, the term “PCR” is well known in the pertinent art. Generally, PCR includes the steps of: (a) obtaining a crude extract containing target DNA molecules from a sample; (b) adding an aqueous solution including an enzyme, a buffer, dNTPs, and oligonucleotide primers to the crude extract; (c) amplifying the target DNA molecules by two- or three-step thermal cycling (e.g., 90-96° C., 72° C., and 37-55° C.) of the resultant mixture; and (d) detecting amplified DNAs.

In the present invention, the PCR may be performed in a polypropylene tube, a 96-well plate, or a silicon-based micro PCR chip.

When the PCR is performed on a silicon-based micro PCR chip, a two-step thermal cycling as well as a three-step thermal cycling can be used. A time required for the PCR on the silicon-based micro PCR chip can be as short as 30 minutes or less. For example, the silicon-based micro PCR chip includes a silicon wafer, a surface of which is formed with a PCR chamber made by silicon lithography and the other surface is formed with a heater for heating the PCR chamber; and a glass wafer having an inlet and an outlet.

›DETAILED DESCRIPTION OF THE INVENTION · 2 of 2

In the present invention, the PCR may be performed using 0.2-1 μM of each primer and 0.01 pg to 1 μg of a template DNA.

In the present invention, the PCR may be performed in three-step thermal cycling conditions of denaturation at 86-97° C. for 1-30 seconds, annealing at 50-70° C. for 1-30 seconds, and extension at 60-72° C. for 1-30 seconds, or in two-step thermal cycling conditions of denaturation at 86-97° C. for 1-30 seconds and annealing and extension at 50-70° C. for 5-30 seconds.

The present invention also provides a SARS-CoV detection kit including the primer set for SARS-CoV detection.

The SARS-CoV detection kit of the present invention may include the primer set, a PCR solution, a buffer, an enzyme, and the like.

Hereinafter, the present invention will be described more specifically by Examples. However, the following Examples are provided only for illustrations and thus the present invention is not limited to or by them.

EXAMPLES

›Examples4

›Example 1

Design of Primers for SARS-CoV Detection

In this Example, there were designed PCR primers for SARS-CoV detection, which are specific to SARS-CoVs and do not react with other coronaviruses.

The genome sequences of 40 strains belonging to SARS-CoVs were searched using the public database (www.ncbi.nlm.nih.gov). Based on the search results, common sequences of the 40 strains were extracted. After sequence homology search between the common sequences and other coronaviruses and other respiratory viruses capable of infecting human bodies, homologous sequences were removed and sequences with no cross reactivity were selected. The results are presented in Table 1 below.

As a result, primers as listed in Table 2 below were selected.

›Example 2

Tube RT-PCR for SARS-CoV RNA Samples

In this Example, RT-PCR was performed on a PCR machine (ABI 2400) using the primer sets of GS-SARS01-06 and SARS-CoV RNA (total RNA samples extracted from SARS-CoVs) as templates. At this time, the concentration of the templates was 2 μg/20 μl. Before initiating PCR, the RNA samples in a 25 μl PCR solution were converted to cDNAs by reverse transcription at 42° C. for 60 minutes. The PCR was performed in three-step thermal cycling conditions as follows: 50 cycles of denaturation at 95° C. for 20 seconds, annealing 65° C. for 40 seconds, and extension at 72° C. for 60 seconds.

The results are shown in FIG. 2 . As shown in FIG. 2 , SARS-CoV RNAs were detected. In FIG. 2 , lane 1 is 1 kb-DNA plus ladder (Invitrogen), lane 2 is a PCR product (156 bp) amplified with GS-SARS01, lane 3 is a PCR product (244 bp) amplified with GS-SARS02, lane 4 is a PCR product (179 bp) amplified with GS-SARS05, lane 5 is a PCR product (103 bp) amplified with GS-SARS06, and lane 6 is a PCR product (118 bp) amplified with GS-SARS04.

›Example 3

RT-PCR for SARS-CoV RNA Samples on Silicon-Based PCR Chip

In this Example, RT-PCR was performed on a PCR machine (GenSpector 1&2) using the primer sets of GS-SARS01-06 and SARS-CoV RNAs (total RNA samples extracted from SARS-CoVs) as templates. At this time, the concentration of the templates was 2.4×10 3 copies. Before initiating PCR, the RNA samples in a 1 μl at PCR solution on a silicon-based PCR chip were converted to cDNAs by reverse transcription at 42° C. for 60 minutes. The PCR was performed in three-step thermal cycling conditions as follows: 50 cycles of denaturation at 92° C. for 1 second, annealing 52° C. for 1 second, and extension at 72° C. for 5 seconds.

The results are shown in FIG. 3 . As shown in FIG. 3 , SARS-CoV RNAs were detected on the silicon-based PCR chip. Each lane of FIG. 3 is as defined in FIG. 2 .

›Example 4

Cross Reactivity Test with Human gDNAs

In this Example, whether the primer sets of GS-SARS01-14 react with human gDNAs was analyzed.

PCR was performed in the same manner as in Example 3 except that 45 cycles were repeated using a 25 μl PCR solution containing 1 ng SARS-CoV cDNAs+200 ng human gDNAs as templates.

The results are shown in FIG. 4 . As shown in FIG. 4 , no cross reactivity with human gDNAs were observed and SARS-CoV RNAs were detected. In FIG. 4 , M is 1 kb-DNA plus ladder (Invitrogen), lane 1 is a PCR product (184 bp) amplified with GS-SARS07, lane 2 is a PCR product (156 bp) amplified with GS-SARS01, lane 3 is a PCR product (275 bp) amplified with GS-SARS09, lane 4 is a PCR product (266 bp) amplified with GS-SARS03, lane 5 is a PCR product (242 bp) amplified with GS-SARS08, lane 6 is a PCR product (244 bp) amplified with GS-SARS02, lane 7 is a PCR product (275 bp) amplified with GS-SARS12, lane 8 is a PCR product (179 bp) amplified with GS-SARS05, lane 9 is a PCR product (103 bp) amplified with GS-SARS03, lane 10 is a PCR product (145 bp) amplified with GS-SARS13, lane 11 is a PCR product (140 bp) amplified with GS-SARS14, lane 12 is a PCR product (118 bp) amplified with GS-SARS04, lane 13 is a PCR product (218 bp) amplified with GS-SARS10, and lane 14 is a PCR product (167 bp) amplified with GS-SARS11.

As apparent from the above description, a primer set of the present invention can be efficiently used in a method for specifically detecting SARS-CoV.

A method for detecting SARS-CoV of the present invention can detect SARS-CoV without cross reaction of the primer set with other coronaviruses.

A SARS-CoV detection kit of the present invention can be used in specifically detecting SARS-CoV.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the following claims.

›Tables in the description — 2

TABLE 1 — Analysis results for cross reactivity using B12Seq or Blastn *NS: No significant homology **PM: Partially matching H_CoV229E: Human coronavirus 229E, H_CoV OC43: Human coronavirus OC43 INFV: Influenza virus type A, B, PINFV: Parainfluenza virus type 1, 2, 3 RSV: Respiratory syncytial virus type A, B ADV: Adenovirus, HMPV: Human metapneumovirus

	H_CoV229	H_CoV						Human
Section	E	OC43	INFV	PINFV	RSV	ADV	HMPV	gDNA
Sequence	NS*	NS	NS	NS	NS	NS	NS	PM**
matching

TABLE 2A — PCR primers for SARS-CoV detection and their characteristics

Primer Set	Primer
No.	No.	Sequence	Position	Length	Tm (° C.)	PCR product (bp)
GS-SARS01	A1F4	SEQ ID NO: 1	3196-3221	26	58.6	156
	A1R4	SEQ ID NO: 2	3328-3351	24	58.4
GS-SARS02	C30F4	SEQ ID NO: 3	10443-10467	25	57.1	244
	C30R4	SEQ ID NO: 4	10662-10686	25	59.7
GS-SARS03	FJF3	SEQ ID NO: 5	20594-20615	22	64.1	266
	FJR3	SEQ ID NO: 6	20836-20859	24	63.8
GS-SARS04	S2F1	SEQ ID NO: 7	24097-24121	25	70.6	118
	S2R1	SEQ ID NO: 8	24187-24213	27	67.8
GS-SARS05	CMF2	SEQ ID NO: 9	26429-26454	26	60.9	179
	CMR2	SEQ ID NO: 10	26584-26607	24	59.1
GS-SARS06	CNF2	SEQ ID NO: 11	28560-28585	26	66.3	103
	CNR2	SEQ ID NO: 12	28640-28662	23	67.5
GS-SARS07	A1F3	SEQ ID NO: 13	3236-3259	24	59.2	184
	A1R3	SEQ ID NO: 14	3398-3419	22	61.3
GS-SARS08	C30F3	SEQ ID NO: 15	10443-10467	25	57.1	242
	C30R3	SEQ ID NO: 16	10659-10684	26	56.0
GS-SARS09	FJF2	SEQ ID NO: 17	20590-20615	26	68.6	275
	FJR2	SEQ ID NO: 18	20839-20864	26	69.5
GS-SARS10	S2F3	SEQ ID NO: 19	24194-24216	23	61.7	218
	S2R3	SEQ ID NO: 20	24388-24411	24	60.5
GS-SARS11	S2F4	SEQ ID NO: 21	24044-24068	25	61.8	167
	S2R4	SEQ ID NO: 22	24187-24210	24	61.4
GS-SARS12	CMF1	SEQ ID NO: 23	26429-26454	26	60.9	275
	CMR1	SEQ ID NO: 24	26677-26703	27	64.4
GS-SARS13	CNF4	SEQ ID NO: 25	28643-28666	24	68.4	145
	CNR4	SEQ ID NO: 26	28764-28787	24	67.3
GS-SARS14	CNF5	SEQ ID NO: 27	28645-28666	22	64.9	140
	CNR5	SEQ ID NO: 28	28764-28784	21	66.5
GS-SARS15	A1F1	SEQ ID NO: 29	3156-3179	24	65.1	267
	A1R1	SEQ ID NO: 30	3398-3422	25	65.4
GS-SARS16	A1F2	SEQ ID NO: 31	3231-3256	26	60.7	121
	A1R2	SEQ ID NO: 32	3327-3351	25	60.9
GS-SARS17	C30F1	SEQ ID NO: 33	10441-10467	27	59.2	246
	C30R1	SEQ ID NO: 34	10660-10686	27	61.2
GS-SARS18	C30F2	SEQ ID NO: 35	10190-10214	25	64.7	102
	C30R2	SEQ ID NO: 36	10265-10291	27	55.2
GS-SARS19	FJF1	SEQ ID NO: 37	20701-20728	28	60.5	115
	FJR1	SEQ ID NO: 38	20794-20815	22	56.2
GS-SARS20	S2F2	SEQ ID NO: 39	24042-24068	27	64.2	175
	S2R2	SEQ ID NO: 40	24191-24216	26	64.8
GS-SARS21	S2F5	SEQ ID NO: 41	24492-24516	25	61.8	123
	S2R5	SEQ ID NO: 42	24595-24614	20	65.5
GS-SARS22	CNF1	SEQ ID NO: 43	28641-28666	26	70.2	151
	CNR1	SEQ ID NO: 44	28766-28791	26	70.0
GS-SARS23	CNF3	SEQ ID NO: 45	28640-28666	27	72.1	150
	CNR3	SEQ ID NO: 46	28764-28789	26	71.9

1 of 11 part labels are ours — the grant heads the rest

Claims as granted

9 claims

Classifications

5 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07H21/04
C12Q1/68

USPC · US Patent Classification

536/24.33435/6435/91.2

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.5 y

1,273 days filing → grant

Office actions

after a restriction

Responses

no RCE

Interviews

examiner interview summaries

Examiner

Gary Benzion

art unit 1637 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 3 back · 2 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.